To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

NCT04801043 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: XNW4107-002
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1, randomized, double-blind, placebo-controlled study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-min (± 3 min) IV infusion in healthy adult young females and in healthy adult elderly males and females.

Conditions

Bacterial Infections

Outcome Measures

Primary Outcomes (11)

• (Plasma)Total body clearance (CL/F) of of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Plasma) Area under the curve from time zero to the last quantifiable sample (AUC0-last) of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Plasma) AUC extrapolated to infinity (AUC0-∞) of of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Plasma) Apparent steady-state volume of distribution (Vss/F) of of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Plasma) Maximum plasma concentration (Cmax) of of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Plasma) Time to the maximum plasma concentration (Tmax) of of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Plasma) The terminal elimination half-life (t1/2) of XNW4107, imipenem and cilastatin.

  From baseline to 48 hours post-dose

• (Urine) Renal clearance (CLR) of the XNW4107, imipenem and cilastatin dose administered.

  From baseline to 48 hours post-dose

• (Urine) Fraction of drug excreted in the urine expressed as a percentage of the XNW4107, imipenem and cilastatin dose administered (Ae%)

  From baseline to 48 hours post-dose

• (Urine) Amount of drug excreted in the urine through 24 hours (Ae0-24)

  From baseline to 24 hours post-dose

• (Urine) Amount of drug excreted in the urine through 48 hours (Ae0-48)

  From baseline to 48 hours post-dose

Secondary Outcomes (7)

• Number of participants with treatment-related adverse events of Hematology as assessed by CTCAE v5.0

  From baseline up to 10 days post-dose

• Number of participants with treatment-related adverse events of Physical Examination as assessed by CTCAE v5.0.

  From baseline up to 10 days post-dose

• Number of participants with treatment-related adverse events of Vital Signs as assessed by CTCAE v5.0.

  From baseline up to 10 days post-dose

• Number of participants with treatment-related adverse events of 12-Lead Electrocardiogram (ECG) as assessed by CTCAE v5.0.

  From baseline up to 3 days post-dose

• Number of participants with treatment-related adverse events of Biochemistry as assessed by CTCAE v5.0.

  From baseline up to 10 days post-dose

Study Arms (4)

Cohort 1: Healthy young females

EXPERIMENTAL

Healthy young females participants, ≥ 18 to ≤ 45 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.

Drug: XNW4107; Drug: Imipenem/Cilastatin

Cohort 2: Healthy elderly males

EXPERIMENTAL

Healthy elderly male participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.

Drug: XNW4107; Drug: Imipenem/Cilastatin

Cohort 3: Healthy elderly females

EXPERIMENTAL

Healthy elderly female participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.

Drug: XNW4107; Drug: Imipenem/Cilastatin

Placebo to XNW 4107 & imipenem/cilastatin

PLACEBO COMPARATOR

Matching placebo for XNW4107 and imipenem/cilastatin

Drug: placebo

Interventions

XNW4107 DRUG

XNW4107 250mg IV over 60 minutes as a single dose

Cohort 1: Healthy young females; Cohort 2: Healthy elderly males; Cohort 3: Healthy elderly females

Imipenem/Cilastatin DRUG

500mg/500mg IV over 60 minutes as a single dose

Cohort 1: Healthy young females; Cohort 2: Healthy elderly males; Cohort 3: Healthy elderly females

placebo DRUG

Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose

Placebo to XNW 4107 & imipenem/cilastatin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Healthy adult female, 18 to 45 years of age (both inclusive) or 65 years or over (≥ 65 years); or healthy adult male 65 years or over (≥ 65 years).
• \. BMI ≥ 18.0 and ≤ 32.0 (kg/m²) and weight between 55.0 and 100.0 kg (inclusive).
• \. Medically healthy without clinically significant abnormalities as assessed by the Investigator based on Screening medical history, physical examination, vital signs, 12-lead ECG, hematology, biochemistry and urinalysis.
• \. Male or female, willing to contracept. If female, must be non-pregnant and non-lactating.
• \. Ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food (coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) or product containing any of these from 48 hours prior to study drug administration until discharge from the clinical unit.

You may not qualify if:

• \. History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, vascular or neurological disease, including any acute illness or surgery within the past 3 months determined by the Investigator to be clinically relevant.
• \. Electrocardiogram (ECG) with QTcF interval duration equal or greater than 450 msec for males and 470 msec for females obtained after at least 5 minutes in a supine or semi-supine position at quiet rest at Screening or Check-In (Day -1).
• \. Subjects who have any of the following abnormalities on laboratory values at Screening or prior confinement including: • White blood cell count \< 3,000/mm³, hemoglobin \< 11g/dL; • Absolute neutrophil count \<1,200/mm³, platelet count \<120,000/mm³; • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 1.5 x the upper limit of normal (ULN) for the reference laboratory.
• \. History of seizure disorder except childhood history of febrile seizures.
• \. Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
• \. Close contact with anyone who tested positive for SARS-CoV-2 infection, or presence of symptoms associated with SARS-CoV-2 infection at Screening or Check-in, or within 14 days prior to Screening.
• \. Recent history (within 6 months) of known or suspected Clostridium difficile infection.
• \. Positive testing for HIV Ab, HBsAg or HCV Ab.
• Positive urine drug or alcohol testing at screening or check-in (Day -1).
• Use of prescription medications (with the exception of hormone replacement therapy and contraceptives), including nonsteroidal anti-inflammatory drugs, sucralfate, or herbal preparations within 7 days before Check in (Day -1), or use of an over-the-counter medication, acetaminophen (\>2 g/day), vitamins, or supplements (including fish liver oils) within 7 days before Check in (Day -1); or probenecid or valproic acid within 30 days before Check in (Day -1).
• \. Receipt of an investigational drug within 30 days or 5 half-lives prior to the first administration of study drug, whichever is longer.
• \. Known history of clinically significant hypersensitivity reaction or anaphylaxis to any medication, or history of clinically significant hypersensitivity to the study drug or any related drugs or to any of the excipients, or significant food intolerance.
• \. Donation of blood or plasma within 30 days prior to dosing, or loss of whole blood of more than 500 mL within 30 days prior to dosing, or receipt of a blood transfusion within 1 year of study enrollment.
• \. Any other condition or prior therapy, which, in the opinion of the Investigator, would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likely to be non-compliant with any study requirements.

Sponsors & Collaborators

• Evopoint Biosciences Inc.: lead

Study Sites (1)

Orlando Clinical Research Center (OCRC)

Orlando, Florida, 32809-3017, United States

Location

MeSH Terms

Conditions

Bacterial Infections

Interventions

Cilastatin, Imipenem Drug Combination

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Intervention Hierarchy (Ancestors)

Imipenem; Thienamycins; Carbapenems; beta-Lactams; Lactams; Amides; Organic Chemicals; Cilastatin; Cyclopropanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Drug Combinations; Pharmaceutical Preparations

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 7, 2021
• First Posted: March 16, 2021
• Study Start: March 2, 2021
• Primary Completion: October 30, 2021
• Study Completion: January 31, 2022
• Last Updated: February 16, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)